3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2/3
2
Phase 2
2
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
2
Carcinoma in Situ
2
Virus Diseases
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Adenoviridae Infections
1
Interventions
Cisplatin
98
Gemcitabine
66
Paclitaxel
62
Carboplatin
60
Fluorouracil
59
Docetaxel
59
Capecitabine
59
Oxaliplatin
56
Cyclophosphamide
54
Radiotherapy
50
Drug Therapy
46
Bevacizumab
38
pembrolizumab
35
Dexamethasone
33
Magnetic Resonance Spectroscopy
32
Leucovorin
32
Doxorubicin
31
Cytarabine
27
Etoposide
26
Pemetrexed
25
Nivolumab
24
Methotrexate
24
Radiation
20
Vincristine
18
venetoclax
17
apatinib
17
Rituximab
17
Prednisone
17
Letrozole
17
Irinotecan
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Interventional
×
valrubicin
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled
NCT01316874
2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3
Completed
90 enrolled